Cambridge UK, 7th November 2011- Antitope Ltd., UK (“Antitope”) today announced a research agreement with Therapure Biopharma Inc., Canada (“Therapure”) for the generation of therapeutic monoclonal antibodies. Under the Agreement, Antitope will apply its proprietary Composite Human Antibody™ technology for the generation of humanized antibodies for a range of clinical indications.
“We are delighted to be working with such an innovative company as Therapure,” said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope, adding, “This partnership utilizes Antitope’s expertise in engineering non-immunogenic humanized antibodies to complement Therapure’s innovations in developing novel therapeutics based on monoclonal antibodies.”
“Therapure is pleased to work with Antitope to develop humanized monoclonal antibodies to support our drug development programs. This is an important next step in the development of our antibodies,” said Dr. David Bell, Chief Scientific Officer of Therapure.
About Antitope Ltd.
Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope’s proprietary Composite Human Antibody™ technology results in the generation of humanized antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide. For further information on Antitope visit www.antitope.co.uk or contact:
Dr Neil Butt
Business Development Director, Antitope Ltd.
Tel: +44 (0)1223 496190
Email: info@antitope.co.uk
About Therapure Biopharma Inc.
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma is also a specialist in therapies derived from hemoglobin, a blood protein. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.
For further information on Therapure visit www.therapurebio.com or contact:
Rajan Puri, Director, Business Development
Therapure Biopharma Inc.
Tel: +1 (905) 286-6232
Email: busdev@therapurebio.com
